Theravance Biopharma Inc
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company focused on respiratory medicines for lung disease, best known for Yupelri, a once-daily inhaled treatment for chronic obstructive pulmonary disease, and for royalty rights in the inhaler Trelegy Ellipta developed with partner GSK. The firm was created in 2014 when the original Theravance split in two, keeping the respiratory business while the rest became Innoviva. Its name blends "therapeutics" and "advance."
3.250% Senior Note
No insider transactions reported in all recorded history.